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The evolution of medicine and medical technology hinges on the successful translation 
of basic science research from the bench to clinical implementation at the bedside. 
Out of the increasing need to facilitate the transfer of scientific knowledge to patients, 
translational research has emerged. Significant leaps in improving global health, such 
as antibiotics, vaccinations, and cancer therapies, have all seen successes under this 
paradigm, yet today, it has become increasingly difficult to realize this ideal scenario. As 
hospital revenue demand increases, and financial support declines, clinician-protected 
research time has been limited. Researchers, likewise, have been forced to abandon 
time- and resource-consuming translational research to focus on publication-generating 
work to maintain funding and professional advancement. Compared to the surge in 
scientific innovation and new fields of science, realization of transformational scientific 
findings in device development and materials sciences has significantly lagged behind. 
Herein, we describe: how the current scientific paradigm struggles in the new health-
care landscape; the obstacles met by translational researchers; and solutions, both 
public and private, to overcoming those obstacles. We must rethink the old dogma of 
academia and reinvent the traditional pathways of research in order to truly impact the 
health-care arena and ultimately those that matter most: the patient.
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inTRODUCTiOn
The “Knowledge Doubling Curve,” coined by Buckminster Fuller, described that, by the end of World 
War II, the totality of human knowledge would double every 25 years (Fuller, 1982). As time has 
passed, this theory has become not only more evident but also more complex, with new scientific 
disciplines being created, each expanding at different rates. Medical knowledge, now, has a doubling 
time every 18 years, while newer disciplines, such as nanotechnology, double on the average of every 
2 years (Densen, 2011). While the breath of knowledge in each subject varies greatly, these figures 
highlight the speed with which advancement now occurs.
The bench to bedside process is founded on the principle of translating findings in basic science 
into therapeutic interventions for patients. This “process” has been fundamental to the imple-
mentation of remarkable achievements, such as statins for dyslipidemia, targeted cancer therapy, 
and anti-hepatic medicines effective in HIV (Muss, 2006; Mora et  al., 2010). Yet so many more 
bench-side success stories have found themselves stranded on the road to translation with negligible 
FiGURe 1 | Operational challenges for translational research and medicine. Adapted from Blumberg et al. Harvard Catalyst Website (https://catalyst.harvard.
edu/). Translational research is an iterative, dynamic, and layered process with several obstacles that must be negotiated (top). These layers include T0, identification 
of clinical problem followed by preclinical and optimization studies to define material candidates for compound synthesis or cellular mechanisms for intervention; T1, 
initial Phase I studies in humans that aim to demonstrate proof of concept and safety; T2, Phase II and III clinical trials that allowed for incremental and sequential 
evaluations and approvals prior to implementation; T3, post-marketing surveillance trials, conducted after the device has been in the market, are used to determine 
long term efficacy, impact on quality of life, and comparison to other similar devices; and T4, outcomes research to determine the impact of effectiveness intervening 
on patients in the general community, cost-effectiveness compared to equivalent technologies. Valley of death (red) comprises research related to the T0, T1, and T2 
stages (Blumberg et al., 2012).
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impact in the clinic. Bioengineering and biotechnology have seen 
a  tremendous explosion of knowledge and innovation (Zucker 
and Darby, 1996), although these discoveries rarely materialize 
into FDA-approved devices or more rarely become commonly 
adopted by the medical community (Bagchi-Sen, 2007). The 
diversity of devices suffers as companies continue to recycle “old” 
materials to streamline the FDA approval process and meet their 
financial goals. New materials continue to be developed and vet-
ted, yet the clinical impact is not felt as many clinicians rely on 
a handful of devices for tissue engineering and reconstruction.
Abdominal wall and orthopedic reconstruction are two of the 
most common surgical genres today. Over 350,000 hernia repairs 
are performed annually, and in 2011, ~25% of all operating 
room procedures performed were musculoskeletal procedures 
(Poulose et al., 2012; Weiss and Elixhauser, 2014). Polypropylene 
was invented over 60 years ago and still remains the most com-
monly used material in abdominal wall repair, although in use 
since the 1950s (Usher et al., 1958). Another example in the delay 
to market of bench-side materials’ success is the use of biologic or 
functionalized biomaterials. Regenerative medicine has reached 
new heights of innovation with the addition of dynamic manufac-
turing processes and novel drug delivery capabilities (Dimmeler 
et al., 2014). At the bedside, though, the use of simple acellular 
matrices prevails in clinical implementation, and use of function-
alized biomaterials is rare (Mariette et al., 2014; Majumder et al., 
2015). The unavailability, lack of options, and prohibitive costs of 
biologic devices has made their implementation as standard of 
care impossible, although they have characteristics known to be 
extremely favorable for tissue repair (Cevasco and Itani, 2012). 
Similarly, the translation of functionalized devices, often catego-
rized as drug–device combinations, through the tireless FDA-
regulatory pathways, halts their progress and ultimately their 
clinical implementation (Meslin et  al., 2013). As we move into 
an era where scientific discovery and advancement occur more 
rapidly every year, the question lingers: why aren’t the advances 
at the bedside commensurate with the advances on the bench?
ARe we SPeAKinG THe SAMe 
LAnGUAGe?
“Bench to bedside” has more recently evolved into the relatively new 
area of investigation known as translational research. Translational 
research describes the iterative process of not only basic science 
discoveries being integrated into clinical applications but also 
clinical needs and observations driving the focus of basic science 
(Figure 1). Fundamental to the translation of scientific discoveries 
to clinical impact is the collaboration and integration of scientists 
with clinicians, as well as the integration of academia, health care, 
and industry. Herein lies the problem. The cultural and academic 
identities of both clinicians and basic scientists are different.
3Fernandez-Moure Lost in Translation
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org June 2016 | Volume 4 | Article 43
Over time, two cultures have evolved in the translational land-
scape: the preclinical and clinical researcher. In his influential 1959 
Rede lecture, British scientist and novelist, Snow, described “The 
Two Cultures.” The thesis of this lecture was that “the intellectual 
life of the whole of western society” was split into two cultures: the 
humanities and the sciences (Snow, 2012). While exaggerated, it 
draws attention to how intelligent people can differ greatly based 
on their perspective and backgrounds. Similarly, the culture of 
preclinical work and clinical work differs. Most basic scientists 
rarely step foot in hospitals while few physicians carry out any 
“wet” lab work past undergraduate or medical school, well before 
they have gained a true understanding of clinical needs. How 
hypotheses are generated, how they are tested, and how they are 
abandoned vary greatly between the two. One example of this lies 
in the current “bench to bedside” paradigm. Phase I clinical trials 
are the initial testing ground for novel treatments that have been 
found successful and potentially profitable. They provide great 
opportunity for groundbreaking bench work to truly prove use-
ful, yet few rarely materialize as Phase II studies due to minimal 
clinical benefit demonstrated and loss of enthusiasm as the next 
wave of bench to bedside therapeutics hits the clinical shore.
Another example of disconnection occurs at the Phase III 
level. In clinical research, if one of the two blinded randomized 
trials fails to show benefit or either fails the entire study, testing 
is abandoned. This concept of halting a study based on a final 
pivotal experiment is absent from preclinical work where it would 
be unheard of to stop an entire line of study because of one result. 
Again, we see where the current scientific environment fails us. 
In this scenario, one would be inclined to learn why Phase II or 
III failed and study the root cause of less than expected efficacy, 
yet there is no room, money, or time to pursue why things did 
not work as planned. Further, because the scientific literary com-
munity is not interested in publishing negative results, many of 
the finding never make it to paper to instruct and guide those on 
the next wave of trials.
LiFTinG THe SiLOS
The success of any translational research program lies in the 
elimination of silos segregating scientists, doctors, and industry 
professionals from each other. While this seems intuitive to 
those engaged in translational medicine, the reality is that in 
most nations, revenue streams are strictly separated between the 
“hospital” and “research institute.” As the landscape of health care 
and reimbursement continues to evolve, clinicians will continue 
to be seen as earners with little to no incentive to spend any 
additional time pursuing innovative collaborative relationships 
in science. This has lead to a deficiency in the development of 
clinician-scientists and translational science collaboration.
The US has been a leader in the implementation of translational 
research partnerships for over 100 years. Since the Flexner Report 
was released, 105 years ago, the tradition of integrating university-
owned hospitals in the research and teaching process has been 
a pillar to medical education and scientific advancement (Beck, 
2004). As a model for this paradigm, Johns Hopkins exemplified 
the system of medical education where university hospitals were 
coupled to research-oriented schools and scientific institutes. 
This model is seen across the nation in such academic institu-
tions as Harvard, Stanford, and Johns Hopkins, to name a few. 
Unfortunately a new breed of medical schools has emerged with 
a distinct separation between academia and health care, which 
is challenging the long-trusted academic paradigm. Frequently, 
clinicians are challenged to decide between “academic” and 
“private” clinical practice. This further widens the divide between 
the clinician and the scientist, a relationship crucial to success of 
translational medicine.
As the world embraces the need for more integrated relation-
ships in health care and science, several initiatives have emerged 
to encourage partnerships. The National Institutes of Health 
(NIH) has led this charge with the development of the National 
Center for Translational Sciences (NCATS). With a focus on 
enabling and encouraging collaborative partnership between, not 
only, clinicians and scientists, but also, academia, health care, and 
pharmaceutical industries, NCAT focuses on bringing scientific 
innovation to the patient community. In 2016, the budget for 
Clinical and Translational Science Awards (CTSA) was $685.417 
million (http://www.ncats.nih.gov/about/center/budget), indi-
cating a substantial commitment toward the translational initia-
tive. The international scientific community has also taken on this 
initiative. Germany has succeeded in promoting translational 
process with the Fraunhofer Institutes and combining training 
programs with industry partnerships. The Fraunhofer Institutes, 
one of the largest organizations for applied research in Europe, are 
strongly linked to industry with a focus on generating products 
for market. Similarly, in Germany, the Helmholtz Society and the 
Translational Centre for Regenerative Medicine (TRM) in Leipzig 
are designed to combine science and technology to translate sci-
ence to health. Lifting the silos and promoting multidisciplinary, 
inter-institutional, and entrepreneurial collaboration will prove 
to overcome some of the current limitations, but a fundamental 
paradigm shift in education and academia must also occur.
TRAininG AnD CAReeR ADvAnCeMenT
A key point of contention for the progression of translational 
research is the length of time and resources required to carry 
out these, often, multiyear projects. A truly translational study 
takes many steps during the preclinical stage before even mak-
ing it to the clinical phase of study. How are those researchers 
undertaking translational efforts to be evaluated and supported? 
Translational study-support programs like those at MIT’s 
Dashpande Center for Technological Innovation, University of 
Southern California’s Stevens Center for Innovation, or Houston 
Methodist Hospital Research Institute’s Translational Research 
Initiatives have evolved to support this work, understanding that 
translational work may not generate traditional career elevating 
metrics. Publication in high impact journal and NIH funding 
are often sacrificed for intellectual property and patents, without 
which, translation would never be achieved. The customary anti-
entrepreneurial world of academia will need a culture shift if they 
are to embrace this new breed of researcher focused on solving 
clinical problems rather than asking more questions about them. 
This will involve rethinking current criteria for promotion, such 
as high impact publications, grants, and invited lectures.
FiGURe 2 | valleys of death. The “valleys of death” concept is used to describe situations where technology failed to reach clinical implementation. Termination of 
studies in Valley 1 when a technology has shown efficacy, yet is unable to obtain financing to take it to commercialization and human trials. Termination of studies in 
Valley 2 is due to a rapid decline of funding during the costly human trial phase and occurs during the stage in-licensed technology becomes an actual revenue-
generating product.
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While regulatory issues and capital generation remain hurdles 
to translational success, a new pipeline of hybrid researchers is 
needed to cultivate the translational landscape. As pressure to 
generate revenue overcomes many clinicians, and scientists find 
it ever more difficult to obtain NIH and equivalent funding, clini-
cian-scientists and applied-scientists must be trained to undertake 
the challenges of navigating an already treacherous path. With 
this must come administrative understanding that translational 
projects take longer and are born out of large multi-institutional 
and multidisciplinary teams where a researchers contributions 
may not be adequately represented. Along this continuum from 
the bedside to bench to bedside live the applied-scientist and the 
clinician-scientist. There needs to be more crossover and integra-
tion between the “two cultures” Snow described over 50  years 
ago. Many times thought to have an identity crisis, emphasis on 
translational research by the NIH and large academic institutions 
has empowered these individuals and highlighted their need 
going forward. Multidisciplinary institutions are primed to carry 
this agenda to fruition.
Training of this new breed of researchers not only requires 
support and understanding but an infrastructure capable of 
providing a favorable and productive environment for success. 
Traditional training schemes continue to promote silos in both 
the basic scientific and clinical realms. These walls must be 
broken down to create the next wave of translational researchers. 
Already, translational research programs in the basic sciences 
are evolving out of the traditional schemes. From the clinical 
standpoint, more focus and institutional support must be given 
to attract physicians to engage in research previously thought 
to have no place in clinical work. The Mayo Clinic Graduate 
School Clinical and Translational Research Program and Brown’s 
Masters in Clinical and Translational Research are two examples 
of multidisciplinary institutions incorporating translational 
research into their curriculums. So too has the American Board 
of Surgery embraced these initiative by offering flexible pathways 
capable of turning out a new generation of surgeon-scientists 
poised to engage in the translational initiatives of the institutions 
they serve. Alternatively, there needs to be tracks where scientists 
engage the clinic to truly understand the disease they are trying 
to impact. For transitional research to succeed and translational 
researchers to emerge from the traditional systems of education, 
there must be a paradigm shift in training and career develop-
ment that lays the foundation for funding and commercializa-
tion of breakthroughs. Breakthroughs, though, are plagued by a 
sequential set of hurdles and valleys that must be navigated in 
order to bring a novel scientific breakthrough to the community.
DeATH vALLeYS OF TRAnSLATiOnAL 
PROGReSS
Novel breakthroughs capable of funding are exciting when they 
occur. They stir up enthusiasm, bring attention to institutions, 
and generate donor revenue (Heinze et al., 2009). For the rela-
tively few advancements developed by researchers at institutions 
where one can out-license the intellectual property, two “valleys 
of death” await the inventors (Figure 2) (Roberts et al., 2012). 
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The first valley of death is the time between the initial discovery 
and the actual out-licensing of the invention. The reason why 
inventions die in this valley is the same reason why many never 
occur in the first place, a lack of resources. While the researcher 
may have done due diligence to prove the in vitro and in vivo 
efficacy of the invention, the institution within which they work 
does not have the resources to efficiently perform the duties 
needed to protect the discovery. Conversely, often the research 
while in possession of a potential blockbuster product may not 
have the resources to execute the comprehensive in  vitro and 
in vivo preclinical studies required to fully demonstrate efficacy 
(Meslin et al., 2013).
From the standpoint of industry, this period is seen in compa-
nies where initial trials drains funds to the point where prospect 
drugs or device never made it to market because they simply ran 
out of money to finish the trials (Murphy and Edwards, 2003). 
The second valley occurs, here, during the in-licensing and trials 
phase. There are few funding mechanisms specifically geared to 
support product-related translational efforts. US Small Business 
Innovation Research/Small Business Technology Transfer 
program is designed to support these efforts but is intended for 
small for-profit entities where the investigator is in the company 
not in an institution. Thus, most funding for novel biomedical 
tools originating at institutions must come from the private sec-
tor (Murphy and Edwards, 2003). Holders in private investment 
funds expect a return on their investment. They understand the 
risky nature of biomedical enterprise and thus, require substantial 
return to compensate for risk. This, again, leads to loss of funding 
when clinical outcomes do not reflect preclinical efficacy. Thus, 
we are again left with inconsistent support to move a potential 
life-saving therapy into clinical implementation.
CATALYSTS FOR TRAnSLATiOn
Bioengineering has entered a transformational era where 
unprecedented breakthroughs and advances hold the promise of 
revolutionizing health-care practice and delivery. At the thresh-
old stands the translational scientist poised to play the critical role 
in the bridging the gap of cultures and yet, as mentioned above, 
hurdles and “valleys of death” plague advancement. The NIH has 
played an integral role in facilitating these collaborations as early 
as the 1980s. Through the Bayh–Dole Act and the Stevenson–
Wydler Act, they strengthened the incentives for academic and 
government institutions to engage with industry in research col-
laborations and partnerships (Schacht, 2000; Mowery et al., 2001). 
Through this legislation, public sector research institutions were 
allowed to own the intellectual property they generated using fed-
eral funding and license it for commercialization. Through this, 
institutions have been able to make effective partnerships with 
the private sector, leading to such advancements as the creation 
and patenting of biologic drug candidates and small molecules 
(Collins and Varmus, 2015).
As drug and device companies continue to cut research and 
development funding and the NIH budget continues to decline, 
the new hybrid of public–private entity relationships may be 
the backbone of translational research. Programs, such as the 
Defense Advanced Research Projects Agency’s (DARPA) Armed 
Forces Institute of Regenerative Medicine (AFIRM), focus on 
translational initiative that will serve military clinical needs. With 
a focus on combat trauma and regenerative medicine solutions, 
DARPA has invested in research with a clear path from discovery 
to commercialization. The multimillion-dollar consortium col-
laborations born out of AFIRM are only considered for funding 
when a commercial entity willing to undertake the commercial 
manufacturing is partnered with the researchers. Launched 
in 2014, an emerging NIH-driven initiative is the accelerating 
medicine partnership (AMP). While not currently focused on 
materials development, the partnership, which is composed of 
the NIH, 10 biopharmaceutical companies, and several non-
profit organizations, has raised over $180 million. A unique and 
groundbreaking element of this public–private partnership is 
the agreement to make all data analyses made during the col-
laboration publicly available for use by the broader health-care 
community. Under the current fiscal limitations of both sectors 
this relationship poises itself to be mutually beneficial for not only 
those involved but those in the medical community. As part of 
the greater medical knowledge explosion, collaborations such as 
these will rapidly accelerate the available data, leading to a greater 
exponential growth of scientific knowledge.
FROM THe BeDSiDe TO THe BenCH AnD 
BACK: ReTHinKinG TRAnSLATiOn
As we rethink the dogma of scientific research around the world, 
we must embrace the new paradigm of translational research 
and realize that the journey begins and ends at the bedside. As a 
health-care community, we must approach our practice honestly 
to admit and identify shortcomings of our care so that we may 
turn to our applied-scientist or clinician-scientist colleagues for 
solutions to these shortcomings. As a scientific community, we 
must open our labs to integrated inter-institutional, multidisci-
plinary collaborations where we acknowledge and reward those 
undertaking the brave task of developing solutions, rather than 
more questions. As administrators, teachers, and mentors, we 
must continue to invest in the new wave of researchers who may 
not fit into the traditional paradigm of academic advancement 
and support the long road of work they have before them. As gov-
ernment agencies, we must continue to build partnerships with 
the private sector to harness the strengths of all parties. Lastly, as 
a whole medical community, we must embrace each other with a 
solitary unifying goal: to act on behalf of our patients and provide 
solutions to their unsolved clinical needs.
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